(NASDAQ: CRIS) Curis's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.85%.
Curis's earnings in 2026 is -$21,165,000.On average, 6 Wall Street analysts forecast CRIS's earnings for 2026 to be -$41,149,814, with the lowest CRIS earnings forecast at -$44,310,986, and the highest CRIS earnings forecast at -$37,244,148. On average, 6 Wall Street analysts forecast CRIS's earnings for 2027 to be -$26,240,461, with the lowest CRIS earnings forecast at -$25,211,423, and the highest CRIS earnings forecast at -$27,012,239.
In 2028, CRIS is forecast to generate -$21,867,051 in earnings, with the lowest earnings forecast at -$21,009,519 and the highest earnings forecast at -$22,510,199.